{"createdAt":"8/2/2020, 2:08:43 PM","timestamp":1596391723715,"Company ID number":"354","DMX_ISSUER_NAME":"Lepu Medical Technology (Beijing) Co., Ltd.","DMX_ISSUER_ID":"IID000000002453035","Country of Classification":"CHINA","name":"Lepu Medical Technology Beijing Co Ltd ","code":"300003","stock_exchange":"Shenzhen Stock Exchange","people":[{"id":"乐普(北京)医疗器械股份有限公司_蒲忠杰","group":"board","name":"蒲忠杰","title":"董事长,董事","isMale":true,"age":"57","degree":"博士","salary":"0.00","stockAmount":"2.27亿","description":"蒲忠杰先生:1963年出生,中国国籍,拥有美国永久居留权,研究生学历、博士学位。曾任北京钢铁研究总院高级工程师,美国佛罗里达国际大学研究助理,美国WP医疗科技公司技术副总经理;现任乐普(北京)医疗器械股份有限公司董事长、总经理、技术总监,乐普生物科技有限公司执行董事、总经理,北京金一文化发展股份有限公司独立董事,兼任国家心脏病植介入诊疗器械及设备工程技术研究中心主任、中国生物材料学会副会长、北京医药行业协会副会长、中国药品监督管理研究会常务理事、全国卫生产业企业管理协会副会长、中关村昌平大健康联盟理事长、中国生物工程学会理事。","lastUpdated":"2020-01-23"},{"id":"乐普(北京)医疗器械股份有限公司_刘艳江","group":"board","name":"刘艳江","title":"副董事长,董事","isMale":true,"age":"60","degree":"硕士","salary":"--","stockAmount":"-","description":"刘艳江先生:1960年出生,中国国籍,无境外永久居留权,研究生学历,硕士学位,研究员。历任中国船舶重工集团公司第七二五研究所(洛阳船舶材料研究所)副主任、主任、所长助理、副所长,第七研究院副院长、第七研究院党组书记、常务副院长,中国船舶重工集团公司党组纪检组副组长、纪检监察部主任、巡视办主任;现任中国船舶集团有限公司第七二五研究所(洛阳船舶材料研究所)所长、党委副书记,洛阳双瑞科技产业控股集团有限公司董事长,中船重工双瑞科技控股有限公司执行董事,洛阳双瑞特种装备有限公司董事长,青岛双瑞海洋环境工程股份有限公司董事长,中国材料研究学会理事,中国船舶工业行业协会理事。","lastUpdated":"2020-01-23"},{"id":"乐普(北京)医疗器械股份有限公司_徐扬","group":"board","name":"徐扬","title":"董事","isMale":true,"age":"53","degree":"硕士","salary":"25.00万","stockAmount":"-","description":"徐扬先生:1967年出生,中国国籍,无境外永久居留权,研究生学历,执业律师。曾任中信律师事务所律师,公诚律师事务所律师,天达律师事务所律师,北京市四海通程律师事务所律师,北京七星华创电子科技股份有限公司独立董事、中外运空运发展股份有限公司独立董事;现任北京重光律师事务所高级合伙人、律师,乐普(北京)医疗器械股份有限公司第四届董事会董事。","lastUpdated":"2020-01-22"},{"id":"乐普(北京)医疗器械股份有限公司_蒲绯","group":"board","name":"蒲绯","title":"董事","isMale":false,"age":"31","degree":"硕士","salary":"--","stockAmount":"-","description":"蒲绯女士:1989年出生,美国国籍,麻省理工学院(MIT)材料工程及管理金融双学位,哈佛大学(HarvardUniversity)应用物理硕士学位。学业期间,赴清华大学经管学院、牛津大学(OxfordUniversity)材料系交流学习。曾任瑞士信贷银行中国香港(CreditSuisseHK)投资银行实习分析师,3M美国明尼苏达矿务及制造业公司(3MUSA)材料研发工程师,宁波未来动力教育有限公司合伙创始人。2017年起任乐普(北京)医疗器械股份有限公司国际贸易部经理,现任乐普(北京)医疗器械股份有限公司国际事业部总监。","lastUpdated":"2020-01-22"},{"id":"乐普(北京)医疗器械股份有限公司_甘亮","group":"board","name":"甘亮","title":"独立董事","isMale":true,"age":"53","degree":"硕士","salary":"--","stockAmount":"-","description":"甘亮先生:1967年出生,中国国籍,无境外永久居留权,中欧工商管理学院工商管理硕士,首批保荐代表人,注册会计师。曾任中信证券股份有限公司董事总经理,鼎晖投资管理有限公司创新成长基金高级合伙人;现任西藏君度投资有限公司创始合伙人、上海博为科技有限公司董事、山东海富电子有限公司董事。","lastUpdated":"2020-01-22"},{"id":"乐普(北京)医疗器械股份有限公司_王立华","group":"board","name":"王立华","title":"独立董事","isMale":true,"age":"57","degree":"硕士","salary":"--","stockAmount":"-","description":"王立华先生:1963年出生,中国国籍,无境外永久居留权,研究生学历,法学硕士,执业律师。曾任北京大学法律系科研和研究生办公室主任,北京大学法律系党委委员、系科研办公主任,北京大学法律系系主任助理、系党委委员,北京市天元律师事务所主任,第七届北京市律师协会、副会长,中国证监会第七届、第八届股票发行审核委员会委员,中国证监会原第三届、新第一、二、三届上市公司并购重组审核委员会兼职委员,北京市西城区第十四届人民代表大会人大代表、区人大内务司法委员会副主任。现任北京市天元律师事务所首席合伙人,海南矿业股份有限公司独立董事,山东步长制药股份有限公司独立董事,民银资本控股有限公司独立董事,西城律协名誉会长,北京仲裁委员会仲裁员。","lastUpdated":"2020-04-21"},{"id":"乐普(北京)医疗器械股份有限公司_曹路","group":"board","name":"曹路","title":"独立董事","isMale":true,"age":"44","degree":"硕士","salary":"--","stockAmount":"-","description":"曹路先生:1976年出生,中国国籍,无境外永久居留权,工商管理硕士(MBA),注册会计师。曾任普华永道中天会计事务所(特殊普通合伙)高级审计师、审计经理、审计高级经理。现任天津开实会计师事务所(普通合伙)合伙人、常熟市汽车饰件股份有限公司独立董事。","lastUpdated":"2020-01-22"},{"id":"乐普(北京)医疗器械股份有限公司_王兴林","group":"supervisoryCommittee","name":"王兴林","title":"监事会主席","isMale":true,"age":"58","degree":"本科","salary":"--","stockAmount":"-","description":"王兴林先生:1962年出生,中国国籍,无境外永久居留权,本科学历,学士学位,高级会计师。历任西安船舶工业公司财务处副处长、处长、副总会计师;中船重工财务公司副总经理,中船重工财务公司总经理兼副董事长,中国船舶重工集团副总会计师兼中船重工财务公司总经理、副董事长,中国船舶重工集团副总会计师兼财务部主任;现任中兴华投(北京)投资基金管理公司董事总经理。","lastUpdated":"2020-01-23"},{"id":"乐普(北京)医疗器械股份有限公司_王君","group":"supervisoryCommittee","name":"王君","title":"监事","isMale":true,"age":"45","degree":"本科","salary":"--","stockAmount":"-","description":"王君先生:1975年出生,中国国籍,无境外永久居留权,大学本科学历,正高级经济师。历任中国船舶重工集团公司第七二五研究所(洛阳船舶材料研究所)法律顾问、办公室副主任、副总法律顾问;现任中国船舶集团有限公司第七二五研究所(洛阳船舶材料研究所)办公室主任、副总法律顾问,洛阳双瑞万基钛业有限公司监事,洛阳双瑞科技产业控股集团有限公司董事。","lastUpdated":"2020-01-22"},{"id":"乐普(北京)医疗器械股份有限公司_杨明","group":"supervisoryCommittee","name":"杨明","title":"职工监事","isMale":true,"age":"54","degree":"本科","salary":"90.00万","stockAmount":"-","description":"杨明先生:1966年4月出生,中国国籍,无境外永久居留权,本科学历、学士学位。2002年6月加入公司,乐普(北京)医疗器械股份有限公司技术质量部经理、市场部经理、临床注册部经理,现任乐普(北京)医疗器械股份有限公司技术副总监、第四届监事会职工监事。","lastUpdated":"2020-01-07"},{"id":"乐普(北京)医疗器械股份有限公司_蒲忠杰","group":"manager","name":"蒲忠杰","title":"总经理","isMale":true,"age":"57","degree":"博士","salary":"0.00","stockAmount":"2.27亿","description":"蒲忠杰先生:1963年出生,中国国籍,拥有美国永久居留权,研究生学历、博士学位。曾任北京钢铁研究总院高级工程师,美国佛罗里达国际大学研究助理,美国WP医疗科技公司技术副总经理;现任乐普(北京)医疗器械股份有限公司董事长、总经理、技术总监,乐普生物科技有限公司执行董事、总经理,北京金一文化发展股份有限公司独立董事,兼任国家心脏病植介入诊疗器械及设备工程技术研究中心主任、中国生物材料学会副会长、北京医药行业协会副会长、中国药品监督管理研究会常务理事、全国卫生产业企业管理协会副会长、中关村昌平大健康联盟理事长、中国生物工程学会理事。","lastUpdated":"2020-01-23"},{"id":"乐普(北京)医疗器械股份有限公司_郭同军","group":"manager","name":"郭同军","title":"董事会秘书,高级副总经理","isMale":true,"age":"54","degree":"博士","salary":"200.0万","stockAmount":"190.1万","description":"郭同军先生:1966年出生,中国国籍,无境外永久居留权,研究生学历,博士学位。历任国家财政部工业交通司主任科员、国家财政部经济贸易司助理调研员、国家财政部国防司处长,中船重工集团规划部副主任、资产部主任,中国重工董事会秘书、副总经理、党委书记,乐普(北京)医疗器械股份有限公司监事会主席,启迪创业投资管理(北京)有限公司副总经理;现任乐普(北京)医疗器械股份有限公司高级副总经理、董事会秘书,北京人寿保险股份有限公司董事。","lastUpdated":"2020-01-23"},{"id":"乐普(北京)医疗器械股份有限公司_王泳","group":"manager","name":"王泳","title":"副总裁,财务总监","isMale":false,"age":"47","degree":"本科","salary":"180.0万","stockAmount":"1.6万","description":"王泳女士:1973年出生,中国国籍,无境外永久居留权,本科学历,学士学位。曾任普华永道中天会计师事务所北京分所审计部高级经理;现任乐普(北京)医疗器械股份有限公司副总经理、财务总监,乐普生物科技有限公司监事,四川睿健医疗科技股份有限公司监事。","lastUpdated":"2020-01-23"},{"id":"乐普(北京)医疗器械股份有限公司_程凡","group":"manager","name":"程凡","title":"副总裁","isMale":true,"age":"53","degree":"博士","salary":"180.0万","stockAmount":"-","description":"程凡先生:1967年出生,中国国籍,无境外永久居留权,本科学历。曾任北京理工大学自动控制系党总支副书记,美国博士伦手术产品公司中国区销售总监,美国圣犹达医疗公司中国区总裁,深圳市惠泰医疗器械有限公司首席执行官;现任乐普(北京)医疗器械股份有限公司副总经理。","lastUpdated":"2020-01-23"},{"id":"乐普(北京)医疗器械股份有限公司_魏战江","group":"manager","name":"魏战江","title":"副总裁","isMale":true,"age":"48","degree":"硕士","salary":"180.0万","stockAmount":"5.7万","description":"魏战江先生:1972年出生,中国国籍,无境外永久居留权,研究生学历,硕士学位,研究员级高级工程师。曾任职于中国船舶重工集团公司第七二五研究所;现任乐普(北京)医疗器械股份有限公司副总经理,中国共产党北京市第十二次代表大会代表。","lastUpdated":"2020-01-23"},{"id":"乐普(北京)医疗器械股份有限公司_张霞","group":"manager","name":"张霞","title":"副总裁","isMale":false,"age":"52","degree":"硕士","salary":"180.0万","stockAmount":"-","description":"张霞女士:1968年出生,中国国籍,无境外永久居留权,研究生学历,硕士学位,研究员级高级工程师。曾任中国船舶重工集团第七二五研究所非金属材料研究室副主任,科技处处长、副总工程师;现任乐普(北京)医疗器械股份有限公司副总经理,中美华世通生物医药科技(武汉)有限公司董事,隆华科技集团(洛阳)股份有限公司独立董事,河南省第十三届人大代表。","lastUpdated":"2020-01-23"},{"id":"乐普(北京)医疗器械股份有限公司_陈娟","group":"manager","name":"陈娟","title":"副总裁","isMale":false,"age":"48","degree":"博士","salary":"130.0万","stockAmount":"1.16万","description":"陈娟女士:1972年出生,中国国籍,无境外永久居留权,研究生学历,博士学位。历任乐普(北京)医疗器械股份有限公司市场总监,现任乐普(北京)医疗器械股份有限公司副总经理。","lastUpdated":"2020-01-23"},{"id":"乐普(北京)医疗器械股份有限公司_张冰峰","group":"manager","name":"张冰峰","title":"副总裁","isMale":true,"age":"40","degree":"硕士","salary":"140.0万","stockAmount":"-","description":"张冰峰先生:1980年出生,中国国籍,无境外永久居留权,研究生学历,硕士学位。曾任ChinaOperVestors,Inc.高级投资经理,乐普(北京)医疗器械股份有限公司投资发展部经理;现任乐普(北京)医疗器械股份有限公司副总经理,上海美雅珂生物技术有限责任公司董事、泰州厚德奥科科技有限公司董事、杭州皓阳生物技术有限公司董事。","lastUpdated":"2020-01-23"},{"id":"乐普(北京)医疗器械股份有限公司_张志斌","group":"manager","name":"张志斌","title":"副总裁","isMale":true,"age":"44","degree":"硕士","salary":"150.0万","stockAmount":"3.11万","description":"张志斌先生:1976年出生,中国国籍,无境外永久居留权,研究生学历,硕士学位。曾任乐普(北京)医疗器械股份有限公司销售部西北/北京大区经理,上海形状记忆合金材料有限公司总经理,乐普(北京)医疗器械股份有限公司市场部总监;现任乐普(北京)医疗器械股份有限公司副总经理。","lastUpdated":"2020-01-23"},{"id":"乐普(北京)医疗器械股份有限公司_林仪","group":"manager","name":"林仪","title":"副总裁","isMale":true,"age":"46","degree":"硕士","salary":"180.0万","stockAmount":"-","description":"林仪先生:1974年出生,中国国籍,无境外永久居留权,研究生学历,硕士学位,MBA学位。曾任广州邮电通讯设备有限公司多媒体副主任,华为技术公司国际营销系统大客户经理,深圳迈瑞生物医疗电子股份有限公司区域销售经理,国际营销部总监,运营管理部总监;现任乐普(北京)医疗器械股份有限公司副总经理。","lastUpdated":"2020-01-23"}],"companyName":"乐普(北京)医疗器械股份有限公司","province":"北京市","englishName":"Lepu Medical Technology (Beijing) Co Ltd","industry":"医药生物 — 医疗器械Ⅱ","website":"www.lepumedical.com","mainBusiness":"医疗器械及其配件的技术开发、生产，销售。","productsName":["冠状动脉扩张用支架输送系统","血管内无载体含药（雷帕霉素）洗脱支架系统","血管内药物(雷帕霉素)洗脱支架系统","生物可吸收冠状动脉雷帕霉素洗脱支架系统","PTCA球囊扩张导管","PTA球囊扩张导管","非顺应性PTCA球囊扩张导管","PTCA导引导丝","造影导丝","一次性使用引流导管及附件"],"actualController":"蒲忠杰","actualControllerSharePercentage":"18.55%","registeredCapital":"17.82亿元","employeeAmount":"8918","phone":"86-010-80120622","location":"北京市昌平区超前路37号","chineseDescription":"乐普(北京)医疗器械股份有限公司的主营业务是医疗器械及其配件的技术开发、生产，销售。公司的主要产品是冠状动脉扩张用支架输送系统、血管内无载体含药（雷帕霉素）洗脱支架系统、血管内药物(雷帕霉素)洗脱支架系统、生物可吸收冠状动脉雷帕霉素洗脱支架系统、PTCA球囊扩张导管、PTA球囊扩张导管、非顺应性PTCA球囊扩张导管、PTCA导引导丝、造影导丝、一次性使用引流导管及附件。公司心血管医疗器械领域自主研发核心重磅产品，技术领先优势明显，尤其心血管领域“介入无植入”技术，引领中国甚至世界的行业发展；现有产品市场占有率继续稳健攀升，进一步扩大与竞争伙伴的领先地位。","foundedDate":"1999-06-11","goPublicDate":"2009-10-30","companyHistory":"乐普（北京）医疗器械股份有限公司（以下简称“公司”或“本公司”）的前身为北京乐普医疗器械有限公司，于1999年6月11日经北京市工商行政管理局批准成立，成立时注册资本1,260.00万元，中国洛阳船舶材料研究所以货币资金出资882.00万元，WPMedicalTechnologies,Inc.（以下简称“美国WP公司”）以专利技术出资378.00万元。上述出资业经北京燕平会计师事务所有限责任公司审验，并出具燕会科验字（2000）第018号验资报告予以验证。\n　　2004年4月，公司增加注册资本3,740.00万元，分别由原股东中国船舶重工集团公司第七二五研究所（原中国洛阳船舶材料研究所，以下简称“七二五所”）以货币资金、实物及专利技术追加投资1,068.00万元，新股东中船重工科技投资发展有限公司（以下简称“中船重工科投”）以货币资金出资1,600.00万元，新股东自然人蒲忠杰以专利技术出资1,008.00万元，新股东自然人苏荣誉以专利技术出资64.00万元，公司的注册资本由1,260.00万元变更为5,000.00万元。上述增资业经北京科勤会计师事务所有限责任公司审验，并出具科勤（2004）验字第020号验资报告予以验证。\n　　2007年3月，公司增加注册资本8,688.89万元，由新股东BrookInvestmentLtd.（以下简称“Brook公司”）以货币资金追加投入，公司的注册资本由5,000.00万元变更为13,688.89万元，新股东Brook公司占增资后公司注册资本的10%。同时，经北京市昌平区商务局批准及公司第二届六次董事会决议审议通过，七二五所将其持有的增资后公司2.25%的股权、中船重工科投将其持有的增资后公司7.75%的股权转让给公司股东Brook公司。上述增资及股权转让业经大信会计师事务有限公司审验，并出具大信京验字（2007）第0005-0006号验资报告予以验证。\n　　2007年7月，公司增加注册资本1,311.11万元，由原股东七二五所、中船重工科投、美国WP公司、Brook公司以货币资金追加投入，公司注册资本由人民币13,688.89万元变更为人民币15,000.00万元。上述增资业经大信会计师事务有限公司审验，并出具大信京验字（2007）第0015号验资报告予以验证。\n　　2007年12月29日，经国防科工委以科工委[2007]807号文、国务院国资委以国资产权[2007]1547号文、商务部以商资批[2007]2144号文批准，由北京乐普医疗器械有限公司原股东七二五所、中船重工科投、Brook公司、美国WP公司、蒲忠杰和苏荣誉作为发起人，以北京乐普医疗器械有限公司截至2007年7月31日止的净资产整体变更设立乐普（北京）医疗器械股份有限公司。北京乐普医疗器械有限公司经审计的账面净资产为人民币29,759.04万元，经评估的净资产为人民币76,548.71万元，将净资产折合为公司的注册资本（股本）人民币29,759.00万元。上述增资业经大信会计师事务有限公司审验，并出具大信京验字（2007）第0021号验资报告予以验证。\n　　2008年5月29日，经商务部商资批[2008]626号文批准，公司以资本公积向全体股东转增股本5,183.00万元、以未分配利润向全体股东送股1,558.00万元，增加股本6,741.00万元，变更后的注册资本为人民币36,500.00万元。上述增资业经大信会计师事务有限公司审验，并出具大信京验字（2008）第0024号验资报告予以验证。\n　　根据公司2008年第一次临时股东大会决议及2009年第一次、第二次临时股东大会决议和修改后的公司章程规定，并经中国证券监督管理委员会证监许可[2009]953号文核准，公司于2009年9月30日向社会公开发行人民币普通股4,100万股。上述增资业经大信会计师事务有限公司审验，并出具大信京验字[2009]第1-0028号验资报告予以验证。\n　　根据公司2009年度股东大会决议，公司于2010年5月以资本公积转增股本40,600万股，上述增资业经大信会计师事务有限公司审验，并出具大信京验字[2011]第1-0094号验资报告予以验证。\n　　根据贵公司第三届董事会第二十三次会议、第三届董事会第二十七次会议和2016年第一次临时股东大会决议和中国证券监督管理委员会证监许可[2016]2964号“关于核准乐普（北京）医疗器械股份有限公司非公开发行股票的批复”的规定，公司非公开发行境内上市人民币普通股38,082,627.00股。本次非公开发行股票已于2017年1月完成。完成后，公司股本增至1,781,652,921.00股。\n　　截至2017年6月30日，公司累计发行股本总数为1,781,652,921.00股，公司注册资本为1,781,652,921.00元。\n    截至2018年6月30日止，本公司累计发行股本总数1,781,652,921.00股，注册资本为1,781,652,921.00元。\n　　截至2018年12月31日止，本公司累计发行股本总数1,781,652,921.00股，注册资本为1,781,652,921.00元。\n　　截至2019年12月31日止，本公司累计发行股本总数1,781,652,921.00股，注册资本为1,781,652,921.00元。收起▲","shareholders":[{"organizationId":"T000122333","holderName":"中国船舶重工集团公司第七二五研究所(洛阳船舶材料研究所)","totalShare":"2.44亿","sharePercentage":"13.70%"},{"organizationId":"","holderName":"蒲忠杰","totalShare":"2.29亿","sharePercentage":"12.87%"},{"organizationId":"","holderName":"WPMEDICALTECHNOLOGIES,INC","totalShare":"1.24亿","sharePercentage":"6.96%"},{"organizationId":"T000125370","holderName":"香港中央结算有限公司","totalShare":"7431.77万","sharePercentage":"4.17%"},{"organizationId":"T001703819","holderName":"北京厚德义民投资管理有限公司","totalShare":"6775.00万","sharePercentage":"3.80%"},{"organizationId":"T004757056","holderName":"宁波厚德义民投资管理有限公司","totalShare":"5295.00万","sharePercentage":"2.97%"},{"organizationId":"T000059560","holderName":"中船重工科技投资发展有限公司","totalShare":"3516.67万","sharePercentage":"1.97%"},{"organizationId":"","holderName":"全国社保基金一一七组合","totalShare":"2200.00万","sharePercentage":"1.23%"},{"organizationId":"","holderName":"中国工商银行股份有限公司-汇添富价值精选混合型证券投资基金","totalShare":"2000.00万","sharePercentage":"1.12%"},{"organizationId":"T000280241","holderName":"中央汇金资产管理有限责任公司","totalShare":"1895.54万","sharePercentage":"1.06%"},{"organizationId":"T000174034","holderName":"北京中关村国盛创业投资中心(有限合伙)","totalShare":"1878.58万","sharePercentage":"1.05%"},{"organizationId":"","holderName":"招商银行股份有限公司-汇添富医疗服务灵活配置混合型证券投资基金","totalShare":"1700.01万","sharePercentage":"0.95%"},{"organizationId":"","holderName":"澳门金融管理局-自有资金","totalShare":"1666.70万","sharePercentage":"0.94%"},{"organizationId":"","holderName":"熊晴川","totalShare":"1600.29万","sharePercentage":"0.90%"},{"organizationId":"","holderName":"挪威中央银行-自有资金","totalShare":"1526.95万","sharePercentage":"0.86%"},{"organizationId":"","holderName":"前海人寿保险股份有限公司-分红保险产品华泰组合","totalShare":"1499.18万","sharePercentage":"0.84%"},{"organizationId":"","holderName":"中国工商银行股份有限公司-易方达创业板交易型开放式指数证券投资基金","totalShare":"1228.72万","sharePercentage":"0.69%"},{"organizationId":"T000026633","holderName":"魁北克储蓄投资集团","totalShare":"1195.27万","sharePercentage":"0.67%"},{"organizationId":"","holderName":"北京磐沣投资管理合伙企业(有限合伙)-磐沣价值私募证券投资基金","totalShare":"1119.21万","sharePercentage":"0.63%"},{"organizationId":"","holderName":"王云友","totalShare":"1067.65万","sharePercentage":"0.60%"},{"organizationId":"","holderName":"全国社保基金一零四组合","totalShare":"1012.78万","sharePercentage":"0.57%"},{"organizationId":"","holderName":"新华人寿保险股份有限公司-分红-个人分红-018L-FH002深","totalShare":"1011.32万","sharePercentage":"0.57%"},{"organizationId":"","holderName":"中国银行股份有限公司-工银瑞信医疗保健行业股票型证券投资基金","totalShare":"965.00万","sharePercentage":"0.54%"},{"organizationId":"","holderName":"鼎晖投资咨询新加坡有限公司-鼎晖稳健成长A股基金","totalShare":"959.80万","sharePercentage":"0.54%"},{"organizationId":"","holderName":"阿布达比投资局","totalShare":"947.97万","sharePercentage":"0.53%"},{"organizationId":"T000059597","holderName":"中国信达资产管理股份有限公司","totalShare":"927.30万","sharePercentage":"0.52%"},{"organizationId":"","holderName":"中国工商银行股份有限公司-汇添富民营活力混合型证券投资基金","totalShare":"805.91万","sharePercentage":"0.45%"},{"organizationId":"","holderName":"科威特政府投资局","totalShare":"659.03万","sharePercentage":"0.37%"},{"organizationId":"","holderName":"全国社保基金五零三组合","totalShare":"650.00万","sharePercentage":"0.36%"},{"organizationId":"","holderName":"中国建设银行股份有限公司-华安创业板50交易型开放式指数证券投资基金","totalShare":"608.00万","sharePercentage":"0.34%"}],"englishDescription":"Lepu Medical Technology (Beijing) Co., Ltd. is a China-based company principally engaged in the research, development, production and sale of cardiovascular related medical equipment, medicines and health products, as well as in the provision of related medical services. The Company鈥檚 main products include stent systems, occluders, bulk drugs, clopidogrel sulfate, atorvastatin calcium tablets, pacemakers, in vitro diagnostic reagents and equipment and surgical instrument, among others. The Company distributes its products in domestic market and to overseas markets.","englishIndustry":"Medical Equipment & Supplies","Price to earnings (ttm)":"49.70","Price to sales (ttm)":"10.07","Price to book (mrq)":"9.58","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"67.49","Lt debt to equity (mrq)":"36.00","Return on investment (ttm)":"14.13","Return on equity (ttm)":"9.49","Income statement":{"Revenue":"7,795.53","Total revenue":"7,795.53","Cost of revenue, total":"2,171.43","Gross profit":"5,624.10","Selling/general/admin. expenses, total":"2,879.61","Research & development":"513.53","Depreciation/amortization":"160.21","Interest exp.(inc.),net-operating, total":"102.34","Unusual expense (income)":"195.91","Other operating expenses, total":"(188.25)","Total operating expense":"5,834.78","Operating income":"1,960.75","Other, net":"102.51","Net income before taxes":"2,063.26","Provision for income taxes":"339.46","Net income after taxes":"1,723.79","Minority interest":"1.51","Net income before extra. items":"1,725.31","Net income":"1,725.31","Income available to com excl extraord":"1,725.31","Income available to com incl extraord":"1,725.31","Diluted net income":"1,725.31","Diluted weighted average shares":"1,769.25","Diluted eps excluding extraord items":"0.98","Dps - common stock primary issue":"0.20","Diluted normalized eps":"1.07","Gain (loss) on sale of assets":"(2.70)"},"Balance sheet":{"Cash":"1.53","Cash & equivalents":"1,790.13","Short term investments":"10.00","Cash and short term investments":"1,801.66","Accounts receivable - trade, net":"2,166.55","Total receivables, net":"2,488.16","Total inventory":"1,004.83","Prepaid expenses":"155.73","Other current assets, total":"184.00","Total current assets":"5,634.38","Property/plant/equipment, total - gross":"3,408.37","Accumulated depreciation, total":"(1,055.62)","Property/plant/equipment, total - net":"2,352.75","Goodwill, net":"2,718.84","Intangibles, net":"2,008.82","Long term investments":"2,718.87","Note receivable - long term":"170.60","Other long term assets, total":"322.04","Total assets":"15,926.29","Accounts payable":"737.71","Accrued expenses":"188.13","Notes payable/short term debt":"2,401.25","Current port. of  lt debt/capital leases":"1,353.05","Other current liabilities, total":"430.37","Total current liabilities":"5,110.50","Long term debt":"2,457.98","Capital lease obligations":"10.32","Total long term debt":"2,468.30","Total debt":"6,222.60","Deferred income tax":"207.10","Minority interest":"522.17","Other liabilities, total":"135.44","Total liabilities":"8,443.51","Common stock, total":"1,781.65","Additional paid-in capital":"2.09","Retained earnings (accumulated deficit)":"5,840.14","Treasury stock - common":"(254.28)","Other equity, total":"113.18","Total equity":"7,482.78","Total liabilities & shareholders' equity":"15,926.29","Total common shares outstanding":"1,769.25","Tangible book value per share, common eq":"1.56"},"Cash flow":{"Cash receipts":"8,046.63","Cash payments":"(1,749.03)","Cash taxes paid":"(984.18)","Changes in working capital":"(3,323.18)","Cash from operating activities":"1,990.26","Capital expenditures":"(563.11)","Other investing cash flow items, total":"(88.11)","Cash from investing activities":"(651.22)","Financing cash flow items":"(372.37)","Total cash dividends paid":"(639.18)","Issuance (retirement) of debt, net":"(537.29)","Cash from financing activities":"(1,548.85)","Foreign exchange effects":"4.39","Net change in cash":"(205.42)"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"42.88","52 Week High":"46.96","52 Week Low":"23.14","Pricing date":"","10 Day Average Trading Volume":"22.79","Market Capitalization":"76,397.27","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"523.95","Beta":"0.98","1 Day Price Change":"0.14","13 Week Price Return (Daily)":"12.52","26 Week Price Return (Daily)":"34.38","5 Day Price Return (Daily)":"2.07","52 Week Price Return (Daily)":"75.23","Year To Date Price Return (Daily)":"29.63","Month to Date Price Return (Daily)":"17.42","Price Relative to S&P500 (4 Week)":"-3.64","Price Relative to S&P500 (13 Week)":"-11.54","Price Relative to S&P500 (26 Week)":"5.25","Price Relative to S&P500 (52 Week)":"19.09","Price Relative to S&P500 (YTD)":"-0.86"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"0.98","EPS excl. Extra Items (TTM)":"0.86","EPS Normalized (Annual)":"1.07","Revenue per Share (Annual)":"4.41","Revenue per Share (TTM)":"4.29","Book Value (Per Share Annual)":"4.23","Book Value (Per Share Quarterly)":"4.48","Tangible Book Value (Per Share Annual)":"1.56","Tangible Book Value (Per Share Quarterly)":"1.81","Cash Per Share (Per Share Annual)":"1.02","Cash Per Share (Per Share Quarterly)":"1.18","Cash Flow (Per Share Annual)":"1.15","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.20","Dividends (Per Share TTM)":"0.20","EBITD (Per Share TTM)":"1.02","EPS Basic excl. Extra Items (Annual)":"0.98","EPS Basic excl. Extra Items (TTM)":"0.86","EPS incl. Extra Items (Annual)":"0.98","EPS incl. Extra Items (TTM)":"0.86","Free Cash Flow (Per Share TTM)":"0.37","Dividend (Per Share 5Y)":"0.13"},"Valuation":{"P/E excl. Extra Items (Annual)":"43.97","P/E excl. Extra Items (TTM)":"49.70","P/E Normalized (Annual)":"40.16","Price to sales (Annual)":"9.80","Price to sales (TTM)":"10.07","Price to Tangible Book (Annual)":"27.73","Price to Tangible Book (Quarterly)":"23.87","Price to Free Cash Flow (Per Share Annual)":"96.96","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"115.24","Price to Book (Annual)":"10.14","Price to Book (Quarterly)":"9.58","P/E Basic excl. Extra Items (TTM)":"41.96","P/E excl. Extra Items High (TTM)":"65.84","P/E excl. Extra Items Low (TTM)":"26.10","P/E incl. Extra Items (TTM)":"49.70","Net Debt (Interim)":"3,255.97","Net Debt (Annual)":"4,420.94","Dividend Yield (5Y)":"0.58","Dividend Yield":"0.47","Current Dividend Yield (TTM)":"0.47"},"Financial Strength":{"Free Cash Flow (Annual)":"787.96","Current Ratio (Annual)":"1.10","Net Interest coverage (Annual)":"22.07","Long Term Debt/Equity (Annual)":"32.99","Payout Ratio (Annual)":"20.51","Quick Ratio (Annual)":"0.91","Total Debt/Total Equity (Annual)":"83.16","Current EV/Free Cash Flow (Annual)":"98.29","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"1.27","Long Term Debt/Equity (Quarterly)":"36.00","Quick Ratio (Quarterly)":"1.05","Total Debt/Total Equity (Quarterly)":"67.49","Free Cash Flow (TTM)":"662.94","Net Interest Coverage (TTM)":"22.05","Payout Ratio (TTM)":"23.18"},"Margins":{"Gross Margin (Annual)":"72.15","Gross Margin (TTM)":"71.02","Net Profit Margin % (Annual)":"22.11","Net Profit Margin (TTM)":"20.23","Operating Margin (Annual)":"25.15","Operating Margin (TTM)":"22.85","Pretax Margin (TTM)":"24.19","Pretax Margin (Annual)":"26.47","Operating Margin (5Y)":"24.48","Pretax Margin (5Y)":"25.37","Free Operating Cash Flow/Revenue (5Y)":"4.56","Free Operating Cash Flow/Revenue (TTM)":"8.74","Gross Margin (5Y)":"67.91","Net Profit Margin (5Y)":"21.32"},"Management Effectiveness":{"Return on Assets (Annual)":"11.11","Return on Equity (TTM)":"9.49","Return on Average Equity (Annual)":"24.92","Return on Average equity (TTM)":"20.67","Return on Investment (Annual)":"17.14","Return on Investment (TTM)":"14.13","Return on Average Assets (5Y)":"9.66","Return on Average Equity (5Y)":"17.73","Return on Investment (5Y)":"14.10","Asset Turnover (Annual)":"0.50","Asset Turnover (TTM)":"0.47","Inventory Turnover (Annual)":"2.43","Inventory Turnover (TTM)":"2.33","Net Income/Employee (Annual)":"207,598.20","Net Income/Employee (TTM)":"172,078.00","Receivables Turnover (Annual)":"3.77","Receivables Turnover (TTM)":"3.45","Revenue/Employee (Annual)":"938,824.50","Revenue/Employee (TTM)":"850,414.90"},"Growth":{"Revenue Growth (Quarterly YoY)":"-11.26","Revenue Growth Rate (5Y)":"36.11","EPS Growth (Quarterly YoY)":"-34.05","EPS Growth (TTM YoY)":"2.36","EPS Growth Rate (5Y)":"30.20","Dividend Growth Rate (3Y)":"26.84","Revenue Growth (TTM YoY)":"11.55","Revenue Growth (Per Share 5Y)":"33.80","Revenue Growth Rate (3Y)":"31.00","EPS Growth Rate (3Y)":"35.58","Book Value Growth Rate (Per Share 5Y)":"16.93","Tangible Book Value Total Equity CAGR (5Y)":"4.52","Capital Spending growth rate 5 year":"34.87","EBITDA CAGR (5Y)":"35.09","EBITDA Interim CAGR (5Y)":"26.38","Free Operating Cash Flow CAGR (5Y)":"46.71","Total Debt CAGR (5Y)":"90.40","Net Profit Margin Growth Rate (5Y)":"-3.99"},"Income Statement":{"Revenue (Annual)":"7,795.53","Revenue (TTM)":"7,584.00","EBITD (Annual)":"2,565.07","EBITD (TTM)":"1,811.40","Earnings Before Taxes (Annual)":"2,063.26","Earnings Before Taxes (TTM)":"1,834.44","Net Income to Common (Annual)":"1,725.31","Net Income to Common (TTM)":"1,526.39","Earnings Before Taxes Normalized (Annual)":"2,259.17","Net Income Available to Common Normalized (Annual)":"1,888.99","Diluted Normalized EPS excl. Extra Items (TTM)":"0.86"}}}